Creating an Assessment Indicator of Quality Culture Development in the Generic Pharmaceutical Industry in Japan

References

1. 1.↵
   1. Tobita Y.,
   2. Yamamoto G.,
   3. Kudou T.,
   4. Yamoto T.

   Recent Non-Conformity with PMDA at Pharmaceutical Manufacturing Sites and Preventing Measures for Reoccurrence of Such Non-Conformity. J. Natl. Inst. Public Health 2022, 71 (2), 140–146. https://www.niph.go.jp/journal/data/71-2/202271020004.pdf

   OpenUrlGoogle Scholar
2. 2.↵
   Ministry of Health, Labour and Welfare.Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices 1960, Act No.145. https://www.mhlw.go.jp/web/t_doc?dataId=81004000&-dataType=0&pageNo=1 (accessed July 1, 2023)

   Google Scholar
3. 3.↵
   Ministry of Health, Labour and Welfare. Ministerial Ordinance on Standards for Manufacturing Control and Quality Control for Drugs and Quasi-drugs. 2004, Ministerial Ordinance No.179. https://www.mhlw.go.jp/web/t_doc?dataId=81aa6647&dataType=0&pageNo=1 (accessed July 1, 2023)

   Google Scholar
4. 4.↵
   Ministry of Health, Labour and Welfare. Promulgation of the Act for Partial Amendment of the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics (PSEHB Notification No. 1204 (1) dated December 4, 2019, Issued by the Director of Pharmaceutical Safety and Environmental Health Bureau, the Ministry of Health, Labour and Welfare). https://www.mhlw.go.jp/web/t_doc?dataId=00tc4641&dataType=1&pageNo=1 (accessed November 25, 2023)

   Google Scholar
5. 5.↵
   Ministry of Health, Labour and Welfare. Partial amendment to the Ministerial Ordinance on Standard for Manufacturing Control and Quality Control for Drugs and Quasi-Drugs. 2021, Ministerial Ordinance No.90. https://www.mhlw.go.jp/web/t_doc?dataId=00tc5900&dataType=1&pageNo=1 (accessed November 25, 2023)

   Google Scholar
6. 6.↵
   Ministry of Health, Labour and Welfare. Notification No.0702-5 of the PED/PSEHB, No.0702-5 of the CND/PSEHB July 2, 2021. https://www.mhlw.go.jp/hourei/doc/tsuchi/T210706I0010.pdf (accessed October 2022)

   Google Scholar
7. 7.↵
   International Conference on Harmonisation. Harmonised Tripartite Guideline: Pharmaceutical Quality System Q10. https://www.pmda.go.jp/files/000156592.pdf (accessed July 1, 2023)

   Google Scholar
8. 8.↵
   Ministry of Health, Labour and Welfare. [Iyakuhin ni kakaru tachiiri kensa tou no tettei ni tsuite.] Notification No.0115-4 of the CND/PSEHB (January 15, 2016).

   Google Scholar
9. 9.↵
   1. Patel P.,
   2. Baker D.,
   3. Burdick R.,
   4. Chen C.,
   5. Hill J.,
   6. Holland M.,
   7. Sawant A.

   Quality Culture Survey Report. PDA J. Pharm. Sci. Technol. 2015, 69 (5), 631–642.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
10. 10.↵
    Chemo-Sero-Therapeutic Research Institute (Kaketsuken). Investigation Report. November 25, 2015. https://www.mhlw.go.jp/file/05-Shingikai-11121000-Iyakushokuhinkyoku-Soumuka/0000106165.pdf (accessed July 1, 2023)

    Google Scholar
11. 11.↵
    1. Kiyohara T.,
    2. Mimura M.,
    3. Hirao S.

    Survey report (in Japanese). https://ajhc.or.jp/siryo/f20210416-3.pdf (accessed July 1, 2023)

    Google Scholar
12. 12.↵
    1. Srinivasan A.,
    2. Kurey B.

    Organizational Culture: Creating a Culture of Quality. Harvard Bus. Rev. 2014, 92 (4), 23–25.

    OpenUrlGoogle Scholar
13. 13.↵
    National Institute of Public Health. No. 202125016A. https://mhlw-grants.niph.go.jp/project/159398 (accessed July 1, 2023)

    Google Scholar
14. 14.↵
    1. Hiroshi F.,
    2. Katsuhiko S.,
    3. Yuka N.,
    4. Mitsutoshi Y.,
    5. Ikuyo Y.

    Results of JMPA GMP Subcommittee Questionnaire. Pharm Tech Japan 2021, 37 (7), 1073–1080.

    OpenUrlGoogle Scholar
15. 15.↵
    Japan Generic Medicines Association. Regarding the Initiatives for Trust Recovery in Generic Medicines. Mar 26, 2021. https://www.jga.gr.jp/news/210326_004466.html (accessed July 1, 2023)

    Google Scholar
16. 16.↵
    1. Friedli T.,
    2. Buess P.,
    3. Köhler S.

    The Impact of Quality Culture on Operational Performance—An Empirical Study from the Pharmaceutical Industry. PDA J. Pharm. Sci. Technol. 2018, 72 (5),531–542.

    OpenUrlAbstract/FREE Full TextGoogle Scholar
17. 17.↵
    1. Yu L. X.,
    2. Kopcha M.

    The Future of Pharmaceutical Quality and the Path to Get There. Int. J. Pharm. 2017, 528 (1-2), 354–359.

    OpenUrlGoogle Scholar
18. 18.↵
    Quality Culture and Its Measurement. https://www.pda.org/pda-europe/news-archive/full-story/2015/01/30/quality-culture-and-its-measurement (accessed July 1, 2023).

    Google Scholar
19. 19.↵
    Data Integrity–Focus on Quality Culture. https://www.pda.org/docs/default-source/website-document-library/chapters/presentations/XXXustralia/data-integrity–-focus-on-quality-culture.pdf?sfvrsn=d89b6381_4 (accessed July 1, 2023)

    Google Scholar
20. 20.↵
    https://www.jga.gr.jp/information/member.html (in Japanese) (accessed July 1, 2023)

    Google Scholar
21. 21.↵
    1. Buell R. W.

    Elevate Employees, Don’t Eliminate Them. Harvard Bus. Rev. Sep-Oct 2021.

    Google Scholar
22. 22.↵
    1. Scholten W.,
    2. de Vries F.,
    3. Besieux T.

    A Better Approach to Avoiding Misconduct. Harvard Bus. Rev. May-June 2022.

    Google Scholar
23. 23.↵
    1. Sucher S. J.,
    2. Gupta S.

    The Trust Crisis. Harvard Bus. Rev. July 2019.

    Google Scholar
24. 24.↵
    Questionnaire Results Regarding Reliability Assurance Confirmation (Analysis of Corporate Culture) (in Japanese). https://www.jga.gr.jp/assets/uploads/2021/50189f5b2548f3afb4c445780464205e372f2713.pdf (accessed July 1, 2023)

    Google Scholar